October 9, 2018
Pancreatic Cancer 2018: Surgical and Medical Treatment
Timothy R. Donahue, MD, and Zev Wainberg, MD
About the Lecture
Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States. It is the second most common cause of gastrointestinal cancers, behind colon cancer. Patients often do not experience symptoms until the cancer involves the surrounding blood vessels or spreads beyond the pancreas, and they are initially treated with chemotherapy and occasionally radiation therapy. Surgical treatment is offered to patients with early-stage tumors that are confined to the region of the pancreas; it includes a Whipple resection, which is a complex surgery. This lecture will address the surgical and medical treatment of patients with both early and late-stage disease. Up to date information on improved survival associated with chemotherapy regimens and biologic agents will be reviewed. We will also highlight the diverse resources that are available at the UCLA Center for Pancreatic Diseases, including clinical trials, palliative treatments, support services, etc.
Timothy R. Donahue, MD is Chief of Gastrointestinal and Pancreatic Surgery, and an Associate Professor of Surgery at the David Geffen School of Medicine at UCLA. He also has a joint appointment in the Department of Molecular and Medical Pharmacology to facilitate his research program. Dr. Donahue is the Director of the General Surgery Residency Program. He is a very busy pancreatic surgeon and performs three to four pancreatic surgeries per week. He is genuinely interested in caring for patients with pancreatic cancer and making sure they receive state-of-the-art care. In addition to his clinical work, Dr. Donahue is the Principal Investigator of a National Institutes of Health-funded research laboratory. His scientific research focuses on developing new drugs and better treatment strategies for patients with pancreatic cancer. To do so, he collaborates with numerous other researchers across the UCLA campus.
Zev Wainberg, MD is an Assistant Professor in the Department of Medicine, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. As a medical oncologist who specializes in gastrointestinal cancers, Dr. Zev Wainberg received his MD from Tel Aviv University Sackler School of Medicine, New York Program in 2000. He did his internship and residency in Internal Medicine at Montefiore Medical Center Moses Division Hospital, Albert Einstein College of Medicine, from 2000-2003. He completed his three-year fellowship in Hematology-Oncology at the David Geffen School of Medicine at UCLA in 2006. He is the Co-director of the UCLA Gastro-Intestinal Oncology Program and the medical director of the UCLA Colorectal Cancer Center. He is certified in InternalMedicine, Hematology, and Oncology. Dr. Wainberg has an active practice and has many clinical trials devoted to these diseases. His research involves a variety of clinical trials in multiple gastrointestinal cancers including pancreas, colon, gastric and esophageal. Dr. Wainberg’s laboratory-based research efforts involve the testing of novel therapeutics against all gastrointestinal cancers. Currently, he is the recipient of several grants focused on the targeting of cancer stem cells and in molecular classification of GI cancers.
7:00 p.m. – 9:00 p.m.
6:45 – 7:00: Arrival & Refreshments
7:00 – 7:15: Kauser Ahmed, PhD, Introduction to Center
7:15 – 7:20: Kauser Ahmed, PhD, Speaker Introduction
7:20 – 8:55: Speaker Presentation, Q&A
8:55 – 9:00: Closing
Ronald Reagan UCLA Medical Center (RRMC) Auditorium,
B Level, Room B130, 757 Westwood Plaza, Los Angeles, CA 90095
Attendance is Free.
Available at the Medical Plaza or Ronald Reagan Medical Center lots for $12.00